HIV pharmacogenetics in clinical practice: Recent achievements and future challenges

Current HIV Research

Volumn 6, Issue 6, 2008, Pages 544-554

  Tozzi, Valerio ^a   Libertone, Raffaella ^a   Liuzzi, Giuseppina ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Antiretroviral therapy; HIV; Hypersensitivity reactions; Pharmacogenetics

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; APOLIPOPROTEIN; ATAZANAVIR; CYTOCHROME P450 2B6; DIDANOSINE; EFAVIRENZ; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 2B7; GLYCINE; GLYCOPROTEIN P; HLA B ANTIGEN; HLA B5701 ANTIGEN; INDINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THREONINE; TRANSMEMBRANE CONDUCTANCE REGULATOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZALCITABINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ABNORMAL DREAMING; AMINOTRANSFERASE BLOOD LEVEL; ANESTHESIA (SENSORY DYSFUNCTION); CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; DIABETES MELLITUS; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DYSESTHESIA; GASTROINTESTINAL DISEASE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERLIPIDEMIA; HYPERSENSITIVITY REACTION; IMMUNOGENETICS; INSOMNIA; INSULIN RESISTANCE; KIDNEY TUBULE DISORDER; LIPODYSTROPHY; LIVER TOXICITY; MITOCHONDRIAL TOXICITY; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN INTERACTION; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SOMNOLENCE; T LYMPHOCYTE ACTIVATION; GENETICS; METABOLISM;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; PHARMACOGENETICS;

EID: 58149214287     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208786501535     Document Type: Review

References (60)

1. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse trancriptase inhibitor abacavir. Clin Ther 2001; 23: 1603-14.
2. Clay PG. The abacavir hypersensitivity reaction: a review. Clin Ther 2002; 24: 1502-14.
3. Peyrieère H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J. Hypersensitivity related to abacavir in two members of a family. Ann Parmacother 2001; 35: 1291-2.
4. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7: 317-23.
5. Martin AM, Nolan D, Gaudieri S, et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180-5.
6. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7 and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
7. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-2.
8. Hughes AR, Mosteller M, Bansal AT, et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5: 203-11.
9. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99-102.
10. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness aalysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 2004; 14: 335-42.
11. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.
12. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 29, 2008. Available at: http://www.hivatis.org [Accessed: 16 April 2008].
13. Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35: 538-9.
14. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38: S80-9.
15. Taiwo BO. Nevirapine toxicity. Int J STD AIDS 2006; 17: 364-70.
16. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19: 97-9.
17. Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20: 1621-6.
18. Gatanaga H, Yazaki H, Tamuna J, et al. HLA-Cw8 primarily associated with hypersensitivity to nevirapine. AIDS 2007; 21: 264-5.
19. Ritchie MD, Haas DW, Motsinger AA, et al. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse transcriptase inhibitor hepatotoxicity. Clin Inf Dis 2006; 43: 779-82.
20. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Inf Dis 2006; 43: 783-6
21. Haas DW, Ribaudo HJ, Kim RB, et al. Pharmacogenetics of efavirenz and central nervous sistem side effects: an Adult AIDS Clinical Trials Group study. AIDS 2004; 18: 2391-400.
22. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15: 1192-4.
23. Rotger M, Colombo S, Furrer H, et al. Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients. Pharmacogenet Genomics 2005; 15: 1-5.
24. Saitoh A, Fletcher CV, Brundage R, et al. Efavirenzz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516-T polymorphism. J Acquir Immune Defic Syndr 2007; 45: 280-5.
25. Rotger M, Tegude H, Colombo S, et al. Predictive value of know and novel alleles of CYP2B6 for Efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 2007; 81: 557-66.
26. Tsuchiya K, Gatanaga H, Tachikawa N, et al. Homozygous CYP2B6 *6 (Q172h and K262R) correlates with high plasma efavirenz concentration in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun 2004; 319: 1322-6.
27. Wang J, Sonnerborg A, Rane A, et al. Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics 2006; 16: 191-8.
28. Ribaudo HJ, Haas DW, Tierney C, et al. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Inf Dis 2006; 42: 401-7.
29. Fellay J, Marzolini C, Meaden ER, et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002; 359: 30-6.
30. Winzer R, Langmann P, Zylli M, et al. No influence of the Pglycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naive HIV-positive patients. Ann Clin Microbiol Antimicrob 2005; 4: 3.
31. Winzer R, Langmann P, Zylli M, et al. No influence of the Pglycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 2003; 8: 531-4.
32. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antirewtroviral regimens containing Efavirenz and/ or Nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis 2005; 192: 1931-42.
33. Motsinger AA, Ritchie MD, Shafer RW, et al. Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study. Pharmacogenet Genomics 2006; 16: 837-45.
34. Busti AJ, Hali RG, Margolis DM. Atazanavir for the treatment of human immunodeficiency virus infection. Pharmacotherapy 2004; 24: 1732-47.
35. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS 2007; 21: 41-6.
36. Anderson PL, Lamba J, Aquilante CL, Shuetz E, Fletcher CV. Pharmacogenetics characteristics of indinavir, zidovudine and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr 2006; 42: 441-9.
37. Rotger M, Taffe P, Bleiber G, et al. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192: 1381-6.
38. Rodriguez-Novoa S, Barreiro P, Rendon A, et al. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C/ T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006; 42: 291-5.
39. Keswani SC, Pardo CA, Cherry CL, Hoke A, McArthur JC. HIV-associated sensory neuropathies. AIDS 2002; 16: 2105-17.
40. Anderson PL, Kakuda TN, Lichtenstein KA. The cellular pharmacology of nucleoside and nucleotide-analogue reverse transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 2004; 38: 734-53.
41. Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretrovirals therapy: an adult AIDS clinical trials group study. AIDS 2005; 19: 1341-9.
42. Canter JA, Haas DW, Kallinpur AR, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J 2008; 8: 71-7.
43. Kallianpur AR, Hulgan T, Canter JA, et al. Hemocromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy. AIDS 2006; 20: 1503-13.
44. Costarelli S, Torti C, Gatta LB, et al. No evidence of relation between peripheral neuropathy and presence of hemochromatosis gene mutations in HIV-1-positive patients. J Acquir Immuno Defic Syndr 2007; 46: 255-6.
45. Cherry CL, Rosenow A, Affandi JS, McArthur JC, Wesselingh SL, Price P. Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts individual's NRTI-SN risk. AIDS Res Hum Retroviruses 2008; 24: 117-23.
46. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patient with HIV infection. AIDS 1999; 13: 2493-505.
47. Wohl DA, McComsey G, Tebas P, et al. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006; 43: 645-53.
48. Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21: 2445-53.
49. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093-9.
50. Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 2003; 32: 48-56.
51. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002; 16: 2013-8.
52. Nolan D, Moore C, Castley A, et al. Tumor necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy. AIDS 2003; 17: 121-3.
53. Tarr PE, Taffe P, Bleiber G, et al. Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005; 191: 1419-26.
54. Fauvel J, Bonnet E, Ruidavets JB, et al. An interaction between apoC-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001; 15: 2397-406.
55. Foulkes AS, Wohl DA, Frank I, et al. Association among race/ ethnicity, APOC-III genotypes, and lipids in HIV-1-infected individuals on antiretrovirals therapy. PLos Med 2006; 3: 337-47.
56. Guardiola M, Ferre R, Salazar J, et al. Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA5-1131T->C gene variation. Clin Chem 2006; 52: 1914-9.
57. Alonso-Villaverde C, Coll B, Gomez F, et al. The Efavirenz induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS 2005; 19: 341-2.
58. Madeddu G, BonfantiP, De Socio GV, et al. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed Pharmacother 2008; 62: 6-11.
59. Izzedine H, Hulot JS, Villard E, et al. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis 2006; 194: 1481-91.
60. Felley C, Morris MA, Wonkam A, et al. The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case control study. AIDS 2004; 18: 1521-7.